SUNNYVALE, Calif., March 12 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company received the 2008 North American Medical Devices Product of the Year award, from global growth consulting company Frost & Sullivan, for its CyberKnife(R) Robotic Radiosurgery System.
The Frost & Sullivan Award for Product of the Year is presented each year to the company that has demonstrated excellence in new product development and launch within its industry. The recipient company must have shown innovation by launching a broad line of emerging products and technologies.
"We are pleased that Frost & Sullivan has ranked Accuray number one in overall product success for 2008," said Euan S. Thomson, Ph.D., president and CEO of Accuray Incorporated. "Receiving a prestigious award like this, which is based upon extensive research and in-depth interviews, demonstrates our established competitive advantage and outstanding achievements over the past year."
To identify the recipient of this award, Frost & Sullivan's analyst team tracks all new product launches, R&D spending, products in development, and new product features and modifications through interviews with market participants, and extensive secondary and technology research. All new product launches and new products in development in each company are then compared and evaluated based on degree of innovation and customer satisfaction.
"Accuray Incorporated has established itself in the field of robotic radiosurgery with the CyberKnife System and continues to expand its product portfolio through the launch of new products," said Archana Swathy, Frost & Sullivan analyst. "The increased use of the CyberKnife has established a transformation in the treatment regime and has also succeeded in expanding its potential. These collective factors make Accuray's CyberKnife Robotic Radiosurgery System the worthiest recipient of the 2008 Frost & Sullivan Medical Devices Product of the Year Award."
For more information about Frost & Sullivan's Best Practices Awards, visit http://www.awards.frost.com.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 125 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: procedure growth, market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2007 fiscal year, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
|SOURCE Accuray Incorporated|
Copyright©2008 PR Newswire.
All rights reserved